A Study of Farxiga (dapagliflozin) versus other glucose-lowering medicines in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i).

Trial Profile

A Study of Farxiga (dapagliflozin) versus other glucose-lowering medicines in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Dapagliflozin (Primary) ; Canagliflozin; Empagliflozin; Ipragliflozin; Luseogliflozin; Tofogliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CVD-REAL 2
  • Most Recent Events

    • 19 Jun 2018 According to an AstraZeneca media release, data from this trial will be presented at the American Diabetes Association's (ADA) 78th Scientific Sessions 2018.
    • 19 Mar 2018 New trial record
    • 12 Mar 2018 The results were presented as a late breaker at the American College of Cardiologys 67th Annual Scientific Session and published in the Journal of the American College of Cardiology, as reported in an AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top